Tissue-agnostic RET inhibition: can you trust your target?
Mené dans 16 pays sur 45 patients atteints d'une tumeur solide de stade avancé présentant une fusion du gène RET (localisation autre que poumon et thyroïde), cet essai panier de phase I/II évalue l'efficacité, du point de vue du taux de réponse objective, et la toxicité du selpercatinib
The field of oncology has changed vastly over the past two decades with the advent of immunotherapy and the expansion of targeted agents. The basket trial design has emerged as a means to evaluate novel treatments in a tissue-agnostic fashion. To date, tissue-agnostic approvals exist for anti-PD-1 antibodies in the setting of mismatch repair deficiency or high microsatellite instability or high tumour mutational burden, as well as TRK inhibitors for NTRK fusions and dabrafenib plus trametinib for BRAFV600E mutations (table). Approvals of several of these drugs were based on analyses of not only so-called anchor malignancies (those in which a given mutation is most prevalent), but also those belonging to the long tail, meaning cancer types less commonly associated with the alteration of interest.
The Lancet Oncology , commentaire, 2021